Data and artificial-intelligence (“AI”) driven, discovery-services company Predictive Oncology’s (NASDAQ: POAI) subsidiary TumorGenesis is developing quicker, less costly and more precise Patient Derived Xenograft (“PDx”) cancer models that better mimic the patient’s tumor. An article discussing the company reads, “TumorGenesis excels not only in identifying cancer cell lines but also in developing a medium necessary … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary’s Revolutionary Technology Enables Faster, More Accurate Tumor Identification”
Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced the extension of its secured promissory note. According to the update, the note’s maturity date was extended from December 31, 2019 to March 31, 2020. … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Extension of Secured Promissory Note”
Several parties have indicated interest in potential acquisition of POAI’s Skyline Medical division The division has seen recent success with growing sales of its patented, FDA-approved STREAMWAY System POAI also regained compliance with Nasdaq’s minimum bid price requirement Predictive Oncology Inc. (NASDAQ: POAI), a company focused on applying artificial intelligence to personalized medicine and drug … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Notes Indications of Interest in Medical Division; Regains Nasdaq Price Compliance”
POAI sees Q3 2019 revenue total $522,696 from $329,930 in Q3 2018 Company reports records sales of proprietary systems, supplies Significant business highlights indicate continued momentum as Predictive Oncology looks to bright future Predictive Oncology Inc. (NASDAQ: POAI), an artificial intelligence (AI) and data-driven functional precision medicine company, released its financial results for Q3 2019, … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Reports 58% Revenue Increase; Notes Business Highlights for Q3 2019”
POAI subsidiary sequencing ovarian cancers as part of CancerQuest 2020 project, building largest ovarian multi-omic database in the world Company’s work designed to speed development of new drugs, provide therapeutic choices Helomics recently signed collaborative agreement with UPMC-Magee to establish data- and artificial-intelligence-driven approach to treating ovarian cancer The power of artificial intelligence (AI) to … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Key Player in AI Implementation in Ovarian Cancer Detection”
Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced updates on the commercialization of its CancerQuest 2020 initiative. According to the update, the Company is confident that its first predictive model of ovarian cancer … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Updates on Commercialization of Cancer Quest 2020 Initiative”
Predictive Oncology subsidiary TumorGenesis developing faster, less costly, and more accurate PDx cancer models that better mimic the patient’s tumor TumorGenesis revolutionary technology will provide pharmaceuticals with quicker and more effective drug development while significantly improving patient outcomes There’s an unmet need for a multi-omic approach (genome, transcriptome, epigenome, proteome, responseome, and microbiome), but such … Continue reading “Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Tech Primed to Play Key Role in Cancer Drug Development Efforts”
Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its receipt of interest from several parties for the possible acquisition of its Skyline Medical division, which produces and sells the STREAMWAY System for disposal of fluids in medical applications. Predictive Oncology previously announced intentions to focus … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Multiple Indications of Interest for Skyline Medical Division”
Predictive Oncology (NASDAQ: POAI) is a knowledge-driven, precision-medicine company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery. An article discussing the company reads, “POAI’s platform, composed of over 150,000 patient tumors, harnesses the power of an individual patient’s tumor to help recommend the best treatment for that patient. This database, which … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Platform Revolutionizing Cancer Treatment”
Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its recent receipt of notification (the “Notification Letter on Compliance”) from the Listing Qualifications Department of the Nasdaq Stock Market Inc. (the “Nasdaq”) that indicates Predictive Oncology has regained compliance with the minimum bid price requirement set … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Regains Compliance with Nasdaq’s Minimum Bid Price Requirement”
